Lantheus (NASDAQ:LNTH) Issues FY 2025 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 7.000-7.200 for the period, compared to the consensus earnings per share estimate of 6.980. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $91.13 on Friday. The stock has a market cap of $6.34 billion, a P/E ratio of 15.34 and a beta of 0.44. Lantheus has a 1-year low of $56.44 and a 1-year high of $126.89. The firm has a fifty day moving average price of $89.80 and a 200 day moving average price of $96.75.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Sell-side analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.